Albumin Shield™-Enabled OV
Undisclosed Solid Tumors
PreclinicalResearch
Key Facts
About Theriva Biologics
Theriva Biologics is advancing a differentiated oncolytic virus platform engineered for systemic intravenous delivery, a key limitation of earlier therapies. Its lead candidate, VCN-01, has demonstrated promising clinical activity in metastatic pancreatic ductal adenocarcinoma (PDAC) and is positioned for a pivotal Phase 3 trial following a positive End-of-Phase 2 FDA meeting. The company's strategy focuses on leveraging its stroma-degrading and Albumin Shield™ technologies to treat difficult-to-treat solid tumors, both as monotherapy and in combination with chemotherapy and immunotherapy.
View full company profileTherapeutic Areas
Other Undisclosed Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Macrophage-Targeting Agonist Antibody | Bolt Biotherapeutics | Phase 1 |
| IMA204 | Immatics Biotechnologies | Phase 1 |
| TAR002 | TargImmune Therapeutics | Pre-clinical |
| TAR003 | TargImmune Therapeutics | Pre-clinical |
| ERAS-113 | Erasca | Discovery |
| Multiple Programs | Aktis Oncology | Discovery |
| BAT5506 | Compugen | Preclinical |
| Precision DACs | Prelude Therapeutics | Discovery |
| V2ACT Immunotherapy | Genelux | Phase 1 |
| ATOR-4066 | Alligator Bioscience AB | Discovery/Preclinical |
| ACR-6840 | Acrivon Therapeutics | Preclinical |
| ADC Program | Lantern Pharma | Discovery/Preclinical |